1. Singh BN. Morbidity and mortality in cardiovascular disorders: Impact of reduced heart rate. J Cardiovasc Pharmacol Therapeut6:313-313, 2001
2.
2. Kannel W, Kannel C, Paffenbarger R, Cupples A. Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J113:1489-1489, 1987
3.
3. Gillum R. The epidemiology of resting heart rate in a national sample of men and women: Association with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors. Am Heart J116:163-163, 1988
4.
4. Gillman M, Kannel W, Belanger A, D'Agostino R. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J125:1148-1148, 1993
5.
5. Habib G. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin Therapeut19 (suppl A):39-39, 1997
6.
6. Hjalmarson A, Gilpin E, Kjekshus J, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol65:547-547, 1990
7.
7. Gundersen T, Gröttum P, Pedersen T, Kjekshus J, for the Norwegian Timolol Multi-center Study Group. Effect of timolol on mortality and reinfarction after acute myocardial infarction: Prognostic importance of heart rate at rest. Am J Cardiol58:20-20, 1986
8.
8. Kjekshus J. Importance of heart rate in determining betablocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol57:43F-43F, 1986
9.
9. The Beta-blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med344:1659-1659, 2001
10.
10. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Betablockers and sudden cardiac death. Ann Intern Med123(5):358-358, 1995
11.
11. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol80(9B):35J-35J, 1997
12.
12. Palatini P, Casiglia E, Julius S, Pesina AC. High heart rate. A risk factor for cardiovascular death in elderly men. Arch Int Med159:585-585, 1999
13.
13. Palatini P. Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens. 17(suppl 3):S3-S3, 1999
14.
14. Shinbane J, Wood M, Jensen D, et al. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol29:709-709, 1997
15.
15. Redfield M, Kay G, Jenkins L, et al. Tachycardia-related cardiomyopathy: A common cause of ventricular dysfunction in patients with referred for atrioventricular ablation. Mayo Clin Proc75:790-790, 2000
16.
16. Pinter A, Dorian P, Paquette M, et al. Left ventricualr performance during acute rate control in atrial fibrillation: The importance of heart rate and agents used. J Pharmacol Therapeut8:17-24, 2003
17.
17. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation98:946-946, 1998
18.
18. Pozolli, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol32:197-204, 1998
19.
19. Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med34:910-910, 1999
20.
20. Tsang TSM, Gersh BJ. Atrial fibrillation: An old disease, a new epidemic. Am J Med113:232-232, 2002
21.
21. Braunwald E. Shattuck lecture. Cardiovascular medicine at the turn of the turn of millenium: Triumphs, concerns and opportunities. N Engl J Med337:1360-1360, 1997
22.
22. Scheinman MM. Atrial fibrillation and congestive heart failure: The intersection of two common diseases. Circulation98:949-949, 1998
23.
23. Grogan M, Smith HC, Gersh BC, Wood DC. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have dilated cardiomyopathy. Am J Cardiol69:1570-1570, 1992
24.
24. Farshi R, Kistner D, Sarma JSM, Longmate JA, Singh BN. Ventricualr rate control in chronic atrial fibrillation during daily activity and programmed exercise. A crossover openlabel study of five drug regimens. J Am Coll Cardiol33: 304-304, 1999
25.
25. Palatini P. Need for revision of the normal limits of resting heart rate. Hypertension33:622-622, 1999
